Dr. Stephenson on the Impact of Active Surveillance in Prostate Cancer

Andrew Stephenson, MD
Published: Friday, Jun 23, 2017



Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses the impact of active surveillance on the field of prostate cancer.

There has been an important paradigm shift in the management of this disease, Stephenson explains. It positively impacts quality of life compared with other therapies for patients with localized prostate cancer, such as surgery and radiation therapy. There have been important developments evolving the techniques of these treatments, but there is still a negative impact on urinary, bowel, and sexual function by many patients treated with these modalities. 

The aggressiveness of prostate cancer has changed substantially, he explains. Therefore, by subjecting all patients to treatment for prostate cancer, clinicians may be subjecting them to harm without any real, clear benefit, Stephenson adds. 


Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses the impact of active surveillance on the field of prostate cancer.

There has been an important paradigm shift in the management of this disease, Stephenson explains. It positively impacts quality of life compared with other therapies for patients with localized prostate cancer, such as surgery and radiation therapy. There have been important developments evolving the techniques of these treatments, but there is still a negative impact on urinary, bowel, and sexual function by many patients treated with these modalities. 

The aggressiveness of prostate cancer has changed substantially, he explains. Therefore, by subjecting all patients to treatment for prostate cancer, clinicians may be subjecting them to harm without any real, clear benefit, Stephenson adds. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x